MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
08 Abril 2024 - 11:00AM
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic, off-the-shelf, invariant
natural killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases, today announced the presentation of data
from MiNK-215, an investigational IL-15 armored fibroblast
activation protein (FAP) targeting CAR-iNKT cell therapy, at the
American Association for Cancer Research (AACR) Meeting in San
Diego, CA.
“MiNK-215 represents a novel cellular therapeutic to overcome
the limitations of immune checkpoint blockade therapy. The data
presented at AACR demonstrate MiNK-215's potential to effectively
combat colorectal liver metastases, offering hope for patients who
have exhausted conventional treatment options,” said Dr. Jennifer
Buell, President and Chief Executive Officer at MiNK. “Furthermore,
these results accentuate MiNK-215's versatility and synergistic
potential when paired with immunotherapies such as Agenus’
botensilimab and balstilimab. This collaboration holds promise in
bolstering the anti-tumor response, particularly in the formidable
realm of microsatellite stable colorectal cancer."
Liver mets have limited the efficacy of immunotherapy in
patients with mismatch repair proficient/microsatellite-stable
(pMMR/MSS) colorectal cancer (CRC). MiNK's innovative iNKT cell
therapy, MiNK-215, has shown the ability to remodel the
immunosuppressive tumor microenvironment within the liver. Human
organoid models of CRC with liver metastases revealed that MiNK-215
exhibits potent anti-tumor activity through multiple mechanisms
that include:
- Tumor stroma remodeling: MiNK-215 effectively
remodels the tumor stroma, the supportive tissue surrounding the
tumor to create a more favorable environment for immune cell
infiltration and activity.
- Immune activation: By reprogramming the tumor
microenvironment (TME), MiNK-215 reduces the presence of
immune-suppressive FAP expressing stellate cells and CXCL-12
expressing cells.
- Enhanced tumor killing: MiNK-215 recruits
tumor-reactive T cells, pivotal in mounting an effective immune
response against the tumor, ultimately leading to enhanced tumor
eradication.
Presentation Details:
Abstract Title: MiNK-215, an IL-15 armored
FAP-targeting CAR iNKT cell therapy, effectively treats human
organoid models of treatment-refractory MSS colorectal cancer (CRC)
liver metastasesAbstract Number:
1331Presenting Author: Shanmugarajan
KrishnanSession: CAR-NK, NK Engagers, and NK
ModulatorsPresentation Session Date and Time:
Monday April 8, 2024, 9:00 a.m. – 12:30 p.m. PST
Data presented at the conference is available to view in the
publications section of the MiNK website
https://minktherapeutics.com/publications/.
About MiNK TherapeuticsMiNK Therapeutics is a
clinical-stage biopharmaceutical company pioneering the discovery,
development, and commercialization of allogeneic invariant natural
killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases. MiNK is advancing a pipeline of both
native and next generation engineered iNKT programs, with a
platform designed to facilitate scalable and reproducible
manufacturing for off-the-shelf delivery. The company is
headquartered in New York, NY. For more information, visit
https://minktherapeutics.com/ or @MiNK_iNKT. Information that may
be important to investors will be routinely posted on our website
and social media channels.
Forward Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the therapeutic and curative potential of
MiNK-215, including the mechanism of action, potency and safety,
interim or top-line data, including statements regarding
preclinical data, the anticipated benefits of MiNK-215 and clinical
development plans and timelines. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially. These forward-looking statements are
subject to risks and uncertainties, including the factors described
under the Risk Factors section of the most recent Form 10-K, Form
10-Q and the S-1 Registration Statement filed with the SEC. MiNK
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
MiNK undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Investor
Contact917-362-1370investor@minktherapeutics.com
Media
Contact781-674-4428communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
MiNK Therapeutics (NASDAQ:INKT)
Gráfica de Acción Histórica
De May 2023 a May 2024